Type of chemotherapy | N (%) |
---|---|
CMF-like | 100 (9.1) |
· Anthracyclines alone (without Taxanes) | 534 (48.8) |
· Anthracyclines plus Taxanes | 420 (38.4) |
· Taxanes alone (without Anthracyclines) | 41 (3.7) |
Type of Taxane | Â |
· Docetaxel | 359 (32.8) |
· Paclitaxel | 102 (9.3) |
Main chemotherapeutic schedules administered | Â |
· Oral classical CMF 6 cycles | 24 (2.2) |
· CMF 6 cycles iv day 1 and 8 q28d | 53 (4.8) |
· CMF 6 cycles iv day 1 q21d | 9 (0.8) |
· CMF 3–4 cycles iv day 1 and 8 q28d | 11 (1.0) |
· AC 4 cycles | 89 (8.1) |
· AC 6 cycles | 27 (2.5) |
· E90C 4 cycles | 56 (5.1) |
· E75C 4 cycles | 9 (0.8) |
· FE75C 6 cycles | 131 (12.0) |
· FE90C 6 cycles | 95 (8.7) |
· FE100C 6 cycles | 29 (2.6) |
· FAC 6 cycles | 8 (0.7) |
· Canadian CEF 6 cycles | 16 (1.5) |
· Epidoxorubicin 4 cycles – CMF 4 cycles | 5 (0.5) |
· AC 4 cycles – CMF 3 cycles | 15 (1.4) |
· FEC 3 cycles - Docetaxel 3 cycles | 118 (10.8) |
· AC/EC 4 cycles - Docetaxel 4 cycles | 127 (11.6) |
· TAC 6 cycles + G-CSF | 29 (2.7) |
· AC/EC 4 cycles - Paclitaxel q3wks 4 cycles | 39 (3.6) |
· FEC/EC 4 cycles - weekly Paclitaxel x 12 | 43 (3.9) |
· A/EP 4 cycles – CMF 4 cycles | 7 (0.6) |
· ET 6 cycles | 12 (1.1) |
· TC 4 cycles | 19 (1.7) |
· TC 6 cycles | 8 (0.7) |
· Others | 116 (10.6) |